{"entity":{"id":"nct06750185","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of BNT317 DL1 in advanced solid tumours, run by BioNTech SE, now recruiting.","summary":"Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06750185 by BioNTech SE, with 248 participants planned, started 2025-01-13 and due to reach its primary completion in 2031-04. Interventions recorded: BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5 and BNT317 DL6.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06750185","url":"https://clinicaltrials.gov/study/NCT06750185"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["biontech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06750185","phase":"1/2","setting":"A Phase I/II, First-in-human, Open-label Trial of the Safety, Efficacy, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Participants With Advanced Solid Tumors","sponsor":"BioNTech SE","enrolled":248,"outcomes":[]},"route":"/trials/nct06750185/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"}]}}